Secondary Logo

Journal Logo

Topic of the Month

The Changing Spectrum of Neonatal Hepatitis

Hadžić, Nedim; Verkade, Henkjan J.

Author Information
Journal of Pediatric Gastroenterology and Nutrition: September 2016 - Volume 63 - Issue 3 - p 316-319
doi: 10.1097/MPG.0000000000001203
  • Free

Neonatal hepatitis is a default diagnosis reached after excluding other more specific causes of prolonged neonatal cholestasis. The purpose of this brief review is to highlight the expanding spectrum of diagnoses causing prolonged neonatal cholestasis of infancy and to address emerging clinical dilemmas about the role of conventional clinical tests such as liver biopsy or dynamic hepatobiliary scintigraphy in the new era. Novel entities and overlapping metabolic conditions are listed, with a hope to increase awareness of practising paediatricians and direct more specific investigations.


  1. Neonatal hepatitis is a diagnosis of exclusion in prolonged cholestasis of infancy and its prevalence has more than halved in recent years.
  2. The reduction is due to advances in biochemical and genetic diagnosis of inherited and metabolic conditions with overlapping clinical presentation in early infancy.
  3. Paediatricians need to look for additional clinical signs, such as ichthyosis, hypertrichosis, cutis laxa, skeletal changes, or congenital deafness, which could point to new conditions emerging in the spectrum of prolonged neonatal cholestasis.
  4. Role of liver biopsy needs to be redefined to exploit genetic and immunohistochemical progress, while the dynamic hepatobiliary radionuclide studies are much less useful in the diagnosis due to poor specificity.
  5. The more sophisticated noninvasive diagnostic investigations are becoming more affordable and are likely to challenge the roles of standard diagnostic methods in the near future.


The latest guidelines for management of neonatal cholestasis were published by NASPGHAN more than 10 years ago (1). Available database information (PubMed, MEDLINE) was searched for terms: neonatal hepatitis (NH), neonatal cholestasis, prolonged conjugated hyperbilirubinaemia, hepatobiliary scintigraphy, and liver biopsy.

NH is usually defined as a syndrome where extensive investigations into anatomic, genetic, or metabolic causes of prolonged neonatal cholestasis (PNC) in neonates have failed to provide an explanation. Often it is, however, neither “neonatal,” as diagnostic investigations usually extend well into early infancy, nor “hepatitis” because biochemical or histopathological features only exceptionally suggest a significant liver inflammation. To add to this semantic conundrum, attributes such as nonspecific, idiopathic, or cryptogenic are often attached to NH. Thanks to the wider availability and lower cost of genetic testing, an increasing number of paediatric liver conditions have become identifiable early in life. The main reason for reducing the proportion of NH in PNC of infancy was the detection of various inherited autosomal recessive causes of familial cholestasis responsible for prolonged hyperbilirubinaemia of infancy. They are listed and referenced in Table 1(2–28), although this compilation is by no means exhaustive.

Genetic causes of prolonged neonatal cholestasis

The prevalence of NH is estimated to be 1 in 2500 live births (29). Recent meta-analysis analysed 17 larger studies including 1692 infants with PNC of infancy and suggested that NH and biliary atresia (BA) each represented around 26% of cases, whereas the remaining half included infection (11%), total parenteral nutrition–associated cholestasis (6%), metabolic disease, alpha-1-antitrypsin deficiency, and perinatal hypoxia/ischemia (4% each) (29). Galactosaemia was the commonest metabolic condition (37%), whereas cytomegalovirus accounted for 32% of the infections. It is interesting that some half a century ago, a single-tertiary centre prospective study of 137 infants found an almost identical proportion of infants to have BA (24%), whereas NH was “diagnosed” in 69% of non-BA children; alpha-1-antitrypsin deficiency was responsible for a majority (75%) of 7% of the identifiable causes (30).

Role of Hepatobiliary Scintigraphy

With regards to the diagnostic work-up of infants with PNC, the most pressing clinical issue is to either demonstrate or to exclude underlying anatomical problems such as BA or congenital choledochal malformations. Patients with BA who undergo their corrective biliary surgery earlier have much better chances of an improved outcome (31). For many years dynamic hepatobiliary radionuclide studies assessing the uptake and excretion of isotopes such as Tc-99 m-labelled iminodiacetic acid and its derivatives have been an important part of the work-up for PNC of infancy. Recent meta-analysis assessed 81 studies using this modality to distinguish NH from BA (32). The authors confirmed a good sensitivity (overall 98.7% range, 98.1%–99.2%), but a poor specificity (overall 70.4%, range, 68.5%–72.2%) of this test. This data questions its non-selective use for patients with children with PNC as this investigation appears not to be specific enough and adds little to the simple clinical observation of stool colour. It comes as no surprise that the premedication for testing improved the test specificity (phenobarbitone [72.2%], phenobarbitone and cholestyramine [70.8%], and ursodeoxycholic acid [84.8%]) (32). It is, however, noteworthy that a retrospective study from India reported a significant improvement in accuracy of demonstrating the patency of biliary tree (36% vs 18%) when betamethasone was added to phenobarbitone as premedication (33). Formal studies for distinguishing different nonanatomical causes of NH have not been reported, but are likely to be even more difficult to set up and interpret. Overall, it appears that the current role of hepatobiliary radionuclide studies in this setting has been considerably diminished.

Role of Liver Biopsy

Many (although not all!) paediatric liver centres use percutaneous liver biopsy in their initial diagnostic work-up to establish whether the clinical suspicion of BA is strong enough to warrant performing intraoperative cholangiography followed by Kasai portoenterostomy, if indicated. Histologically, NH is commonly associated with giant cell hepatitis, combined with different degrees of portal and lobular inflammation, canalicular cholestasis, bile duct reduplication, extramedullary haemopoiesis, and mild fibrosis (34). The role of liver biopsy is being re-evaluated due to its perceived invasive nature (35), but also in the light of emerging diagnostic technologies, such as whole genome/exome sequencing proteomics (36) or metabolomics (37). With standard precautions in place, the liver biopsy is safe and still remains the most reliable and rapidly informative diagnostic tool in paediatric hepatology (35). Presence of microvesicular or macrovesicular steatosis, prominent macrophages, or damaged mitochondria could assist in arranging further tests for suspected metabolic conditions. With added immunohistological and in situ genetic investigations it potentially not only points to further diagnostic steps, but also could contribute to unravelling of pathogenesis, which have been proven instrumental in defining and advancing our understanding of progressive familial cholestasis syndromes (36). Therefore, progress in genetic medicine needs to be integrated into a comprehensive immunohistochemical work-up if a key diagnostic role of the liver biopsy is to be maintained.

The commonest single cause for PNC remains BA, which occurs sporadically. Many of the conditions associated with neonatal cholestasis will, however, often have overlapping clinical, biochemical, and even histological features. In the context of consanguinity or familial recurrence of NH, additional effort should always be made to try to decipher the aetiology, which may well be genetic or metabolic. In the era of increasingly laboratory-dominated medicine there is a risk that conventional clinical assessment may be deemed less relevant. Our view is that there is still no substitute for an observant paediatrician detecting more subtle clinical signs, reporting, and correlating them with the sophisticated biochemical and genetic investigations and available literature.

Many clinicians have noted the relevance of pursuing further genetic investigations, in particular when low levels of serum gamma-glutamyl transpeptidase are seen in a cholestatic infant (38). These children are generally thought to have less good prognosis, in contrast with the others with NH, where no cause is identified. Attempts to correlate the outcome of certain cholestatic conditions with the serum gamma-glutamyl transpeptidase levels at presentation have had mixed success, possibly due to a number of physiological confounding factors, such as gestational age, birth weight, lack of enteral feeding, but also regional ethnic, metabolic or cultural differences, and so on (39). New challenges for attending paediatric hepatologists are to be aware of and to link clinical signs, seen in some of these newly described associations, with NH. For example, cutis laxa or hypertrichosis in transaldolase deficiency (10), severe eczema in neonatal ichtyosis-sclerosing cholangitis syndrome (19), extrahepatic manifestations such as deafness, chronic diarrhoea in familial intrahepatic cholestasis-1 disease (2) or TJP2 deficiency (7), or bone changes in arthrogryposis-renal dysfunction-cholestasis (8,9) syndrome could be the clues for accurate diagnosis. This awareness could facilitate the direction of specific biochemical and genetic investigations until the time when so-called “neonatal cholestasis genetic panels” become reliable, affordable, and comparable. Additional desirable feature of the genetic tests should be their rapid turnover, which would secure them a place in the time-constrained algorithm for the differentiation of BA from other causes.

It is tempting to speculate that in such a diverse area of PNC of infancy, the emerging sophisticated diagnostic methods based on ultraspecific identification of altered metabolic pathways and specific biomarkers could play a contributory role (40). Metabolomics, for example, using proton nuclear magnetic resonance spectroscopy, could detect compounds related to genetic modification or pathophysiological stimuli (41). Zhao et al used liquid chromatography-tandem mass spectrometry to assess metabolite differences between NH, BA, and controls, and concluded that serum threonine levels were higher in the infants with NH (37). Zhou et al suggested that infants with NH have lower taurochenodeoxycholic acid and higher chenodeoxycholic acid levels than those with BA (42). In contrast, 1 earlier study from the UK could not demonstrate differences on the neonatal blood spots between NH and other forms of PNC of infancy (43). Currently, there are no reliable noninvasive markers to distinguish BA from other causes of PNC in early infancy. It appears that at present time we are not yet able to translate the exciting developments in laboratory technologies to clinical paediatric hepatology practice.

We anticipate that in the not too distant future it will be possible to perform a genetic panel for neonatal cholestasis which will be inexpensive, rapid, and comprehensive enough to detect the majority of mutation-related conditions. Even now there are centres where large-scale testing such as whole genome or whole exome sequencing could be performed at acceptable costs. This will undoubtedly improve and refine diagnostics and further reduce the reported prevalence of the NH syndrome. Performing such extensive genetic tests in young infants will, however, bring about complex ethical and legal issues, which will need to be fully clarified before their definite implementation. Finally, as the heterozygous states within the spectrum of progressive familial cholestasis have been associated with transient PNC and benign outcome (44,45), it remains conceivable that underlying isolated or combined genetic variations and even polymorphisms for some other existing or yet unidentified inherited disorders could play a role during this physiologically challenging period of early infancy. Thus, the clinical relevance of certain types of mutations, carrier states, and genetic polymorphisms will need ongoing future study.


1. Moyer V, Freese DK, Whitington PF, et al. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:115–128.
2. Bull LN, Van Eijk MJ, Pawlikowska L, et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998; 18:219–224.
3. Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998; 20:233–238.
4. Gonzales E, Cresteil D, Baussan C, et al. SRD5B1 (AKR1D1) gene analysis in delta(4)-3-oxosteroid 5beta-reductase deficiency: evidence for primary genetic defect. J Hepatol 2004; 40:716–718.
5. Schwarz M, Wright AC, Davis DL, et al. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis. J Clin Invest 2000; 106:1175–1184.
6. Setchell KD, Schwarz M, O’Connell NC, et al. Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998; 102:1690–1703.
7. Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet 2014; 46:326–328.
8. Gissen P, Johnson CA, Morgan NV, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 2004; 36:400–404.
9. Cullinane AR, Straatman-Iwanowska A, Zaucker A, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet 2010; 42:303–312.
10. Valayannopoulos V, Verhoeven NM, Mention K, et al. Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease. J Pediatr 2006; 149:713–717.
11. De Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95:282–287.
12. Spinner NB, Colliton RP, Crosnier C, et al. Jagged1 mutations in Alagille syndrome. Hum Mutat 2001; 17:18–33.
13. Spinner NB, Leonard LD, Krantz ID. Pagon RA, Adam MP, Ardinger HH. Alagille Syndrome. University of Washington, Seattle, GeneReviews(R). Seattle, WA: 1993.
14. Perlmutter DH. The cellular basis for liver injury in alpha 1-antitrypsin deficiency. Hepatology 1991; 13:172–185.
15. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA [published erratum appears in Science 1989; 245:1437]. Science 1989; 245:1066–1073.
16. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059–1065.
17. Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J Hum Genet 2002; 47:333–341.
18. Phillips MJ, Azuma T, Meredith SL, et al. Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet 2003; 362:1112–1119.
19. Hadj-Rabia S, Baala L, Vabres P, et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004; 127:1386–1390.
20. Bull LN, Roche E, Song EJ, et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000; 67:994–999.
21. Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997; 277:228–231.
22. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin Liver Dis 2007; 27:243–250.
23. Chagnon P, Michaud J, Mitchell G, et al. A missense mutation (R565W) in cirhin (FLJ14728) in North American Indian childhood cirrhosis. Am J Hum Genet 2002; 71:1443–1449.
24. Lumbroso S, Paris F, Sultan C, et al. Activating Gsalpha mutations: analysis of 113 patients with signs of McCune-Albright syndrome--a European Collaborative Study. J Clin Endocrinol Metab 2004; 89:2107–2113.
25. Hadchouel M. Paucity of interlobular bile ducts. Semin Diagn Pathol 1992; 9:24–30.
26. Kaufman FR, Costin G, Thomas DW, et al. Neonatal cholestasis and hypopituitarism. Arch Dis Child 1984; 59:787–789.
27. Makrythanasis P, Van Bon BW, Steehouwer M, et al. MLL2 mutation detection in 86 patients with Kabuki syndrome: a genotype-phenotype study. Clin Genet 2013; 84:539–545.
28. Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta 2012; 1822:1430–1441.
29. Gottesman LE, Del Vecchio MT, Aronoff SC. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr 2015; 15:192.
30. Mowat AP, Psacharopoulos HT, Williams R. Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child 1976; 51:763–770.
31. Davenport M, Ong E, Sharif K, et al. Biliary atresia in England and Wales: results of centralization and new benchmark. J Pediatr Surg 2011; 46:1689–1694.
32. Kianifar HR, Tehranian S, Shojaei P, et al. Accuracy of hepatobiliary scintigraphy for differentiation of neonatal hepatitis from biliary atresia: systematic review and meta-analysis of the literature. Pediatr Radiol 2013; 43:905–919.
33. Gupta DK, Charles AR, Srinivas M, et al. Betamethasone in plus phenobarbitone prior to hepatobiliary scintigraphy increases diagnostic accuracy in infants with jaundice. Indian J Pediatr 2001; 68:1039–1041.
34. Torbenson M, Hart J, Westerhoff M, et al. Neonatal giant cell hepatitis: histological and etiological findings. Am J Surg Pathol 2010; 34:1498–1503.
35. Dezsőfi A, Baumann U, Dhawan A, et al. Liver biopsy in children: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2015; 60:408–420.
36. Crutchfield CA, Thomas SN, Sokoll LJ, et al. Advances in mass spectrometry-based clinical biomarker discovery. Clin Proteomics 2016; 13:1.
37. Zhao D, Han L, He Z, et al. Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome. PLoS One 2014; 9:e85694.
38. Maggiore G, Bernard O, Riely CA, et al. Normal serum gamma-glutamyl-transpeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis. J Pediatr 1987; 111:251–252.
39. Lu FT, Wu JF, Hsu HY, et al. γ-Glutamyl transpeptidase level as a screening marker among diverse etiologies of infantile intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2014; 59:695–701.
40. Ellis DI, Dunn WB, Griffin JL, et al. Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 2007; 8:1243–1266.
41. Amathieu R, Triba MN, Goossens C, et al. Nuclear magnetic resonance based metabolomics and liver diseases: recent advances and future clinical applications. World J Gastroenterol 2016; 22:417–426.
42. Zhou K, Wang J, Xie G, et al. Distinct plasma bile acid profiles of biliary atresia and neonatal hepatitis syndrome. J Proteome Res 2015; 14:4844–4850.
43. Mushtaq I, Logan S, Morris M, et al. Screening of newborn infants for cholestatic hepatobiliary disease with tandem mass spectrometry. BMJ 1999; 319:471–477.
44. Jacquemin E, Malan V, Rio M, et al. Heterozygous FIC1 deficiency: a new genetic predisposition to transient neonatal cholestasis. J Pediatr Gastroenterol Nutr 2010; 50:447–449.
45. Hermeziu B, Sanlaville D, Girard M, et al. Heterozygous bile salt export pump deficiency: a possible genetic predisposition to transient neonatal cholestasis. J Pediatr Gastroenterol Nutr 2006; 42:114–116.
Copyright 2016 by ESPGHAN and NASPGHAN. Unauthorized reproduction of this article is prohibited.